Retrophin Inc.


Stock Update (NASDAQ:RTRX): Retrophin Inc Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis

Retrophin Inc (NASDAQ:RTRX) announced positive top-line results from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a …

A Roundup of Our Top Stories in Healthcare From the Week

One of the more anticipated events of early 2015 played out on Friday – detailed results from an early study of Biogen Idec Inc's (NASDAQ:BIIB) experimental …

Retrophin’s Busy Week: A Financing, a Drug Approval and a Valuable FDA Voucher

Just a day after Retrophin Inc. (NASDAQ:RTRX) announced a $100 million financing the U.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts